Building portfolio of therapeutic options for COVID-19 patients: Harsh Vardhan

One prophylactic trial of 'Aswagandha' and three trials of 'Guduchi plus Pippali'; Yashtimadhu; and polyherbal AYUSH drug (AYUSH-64), are planned on moderately-ill COVID-19 patients, he said.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3bZPTpm
via IFTTT